Market Size of Global Polycystic Ovarian Syndrome Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Polycystic Ovarian Syndrome (PCOS) Treatment Market Analysis
The polycystic ovarian syndrome (PCOS) treatment market is expected to register a growth rate of 5.2% over the forecast period., 2022-2027.
The outbreak of COVID-19 had a significant impact on the healthcare industry. The polycystic ovarian syndrome (PCOS) treatment market is not immune to the effects of the pandemic, which had ramifications for many surgical procedures, including laparoscopic ovarian drilling. Various governments' imposition of lockdown and social distancing restrictions to combat the COVID-19 pandemic outbreak resulted in the suspension of various operations, supply chain disruptions, stifling business growth, and the suspension of new developments, all of which negatively impacted the market. Moreover, according to the study titled 'Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic' published in the BMC Medicine in July 2020, Women with PCOS and other key risk factors for poor COVID-19 clinical outcomes suggest that this common female patient population may be at higher risk than expected if infected with SARS-CoV-2. Thus, the polycystic ovarian syndrome market was significantly impacted by COVID-19.
PCOS is a common hormonal endocrine disorder that affects women of childbearing age (15 to 49 years). According to the Centers for Disease Control & Prevention (CDC) May 2022, PCOS is the most common cause of female infertility. Also, as per a study titled 'The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study,' published in the Frontier in Endocrinology in March 2022, PCOS (polycystic ovary syndrome) is the most common endocrine disorder in women of reproductive age, affecting 6-12% of them.
The increasing burden of PCOS and the unavailability of targeted therapy for PCOS in the market create a need to develop treatment therapies. The players in the market are currently focusing on the unmet market need and on strengthening their pipelines to leverage the opportunities; the commercialization of these robust pipelines is expected to propel market growth. For instance, in January 2020, Abbvie was working on a clinical trial for the chemical Elagolix, which was being evaluated for safety and efficacy in women with polycystic ovary syndrome. Elagolix's safety and efficacy in women with polycystic ovarian syndrome are currently being evaluated in Phase 2 multicenter, double-blind, randomized, placebo-controlled study (PCOS). Such developments are expected to boost the market over the forecast period.
Also, there have been several initiatives by private and government firms to increase awareness about the disease, which is also expected to drive the market. For instance, in June 2020, the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Diabetes and Digestive and Kidney Diseases funded a study on 'Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis' and reported that polycystic ovary syndrome might have at least two different subtypes.
However, the side effects of symptomatic treatment drugs and the lack of approved drugs directly targeting PCOS disease drugs act as among the major restraints to the PCOS treatment market.
Polycystic Ovarian Syndrome (PCOS) Treatment Industry Segmentation
The drugs for treating PCOS are majorly related to symptomatic disease treatment, and substantial opportunities lie for biopharmaceutical companies to invest in this gynecological disorder. The polycystic ovarian syndrome treatment market is segmented by treatment (drug class: contraceptives, insulin-sensitizing agent, antidepressant, anti-obesity, others, and surgeries: ovarian wedge resection, laparoscopic ovarian drilling, other surgeries) and geography (North America, Europe, Asia-Pacific, the Middle-East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Treatment | |||||||
| |||||||
|
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Polycystic Ovarian Syndrome Treatment Market Size Summary
The polycystic ovarian syndrome (PCOS) treatment market is poised for growth, driven by the increasing prevalence of this common hormonal disorder among women of childbearing age. The market is experiencing a resurgence as healthcare providers resume normal surgical procedures, such as laparoscopic ovarian drilling, which remains a preferred treatment due to its cost-effectiveness and high success rate. The COVID-19 pandemic initially disrupted the market, impacting surgical procedures and supply chains, but regulatory guidelines have since facilitated the return to standard practices. The market is also witnessing a surge in research and development efforts, with pharmaceutical companies focusing on developing targeted therapies to address the unmet needs in PCOS treatment. This includes ongoing clinical trials for new drugs, such as Elagolix, which are expected to enhance treatment options and drive market expansion.
In North America, the market is further bolstered by the rising prevalence of obesity, a significant risk factor for PCOS, and increased awareness of the condition. The region's advanced healthcare infrastructure and strong product pipeline contribute to its leading position in the market. Major players, including Bayer AG, Pfizer, and Teva Pharmaceutical Industries, are actively involved in research and development, with several drugs in clinical trials. Collaborations and acquisitions, such as Organon's acquisition of Forendo Pharma, highlight the industry's commitment to advancing PCOS treatments. Despite challenges like the side effects of symptomatic treatments and the lack of approved drugs targeting PCOS directly, the market is expected to grow steadily, supported by ongoing innovations and strategic partnerships.
Global Polycystic Ovarian Syndrome Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increased Burden of PCOS
-
1.2.2 Growth in Initiatives by Government and Private Players to Raise Awareness
-
-
1.3 Market Restraints
-
1.3.1 Adverse Effects Associated with Treatment
-
1.3.2 Lack of FDA Approved Drugs Specific to Polycystic Ovarian Syndrome (PCOS)
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Treatment
-
2.1.1 Drug Class
-
2.1.1.1 Contraceptives
-
2.1.1.2 Insulin-sensitizing Agent
-
2.1.1.3 Antidepressants
-
2.1.1.4 Anti-obesity
-
2.1.1.5 Other Drug Classes
-
-
2.1.2 Surgery
-
2.1.2.1 Ovarian Wedge Resection
-
2.1.2.2 Laparoscopic Ovarian Drilling
-
2.1.2.3 Other Surgeries
-
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Mexico
-
-
2.2.2 Europe
-
2.2.2.1 France
-
2.2.2.2 Germany
-
2.2.2.3 United Kingdom
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Rest of Europe
-
-
2.2.3 Asia-Pacific
-
2.2.3.1 China
-
2.2.3.2 Japan
-
2.2.3.3 India
-
2.2.3.4 Australia
-
2.2.3.5 South Korea
-
2.2.3.6 Rest of Asia-Pacific
-
-
2.2.4 Middle-East and Africa
-
2.2.4.1 GCC
-
2.2.4.2 South Africa
-
2.2.4.3 Rest of Middle-East and Africa
-
-
2.2.5 South America
-
2.2.5.1 Brazil
-
2.2.5.2 Argentina
-
2.2.5.3 Rest of South America
-
-
-
Global Polycystic Ovarian Syndrome Treatment Market Size FAQs
What is the current Global Polycystic Ovarian Syndrome Treatment Market size?
The Global Polycystic Ovarian Syndrome Treatment Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Global Polycystic Ovarian Syndrome Treatment Market?
Pfizer Inc., Teva Pharmaceutical Industries Limited, Novartis International AG, Takeda Pharmaceutical Company Limited and Bayer AG are the major companies operating in the Global Polycystic Ovarian Syndrome Treatment Market.
